Title:
ANTIGEN-BINDING MOLECULE SPECIFICALLY BINDING TO DLL3 AND CD3, AND PHARMACEUTICAL USE THEREOF
Document Type and Number:
WIPO Patent Application WO/2023/246885
Kind Code:
A1
Abstract:
The present disclosure relates to an antigen-binding molecule specifically binding to DLL3 and CD3, and pharmaceutical use thereof. The antigen-binding molecule can be used for treating cancers.
Inventors:
YE XIN (CN)
YAO QINGQING (CN)
JIN XINSHENG (CN)
YING HUA (CN)
TAO WEIKANG (CN)
YAO QINGQING (CN)
JIN XINSHENG (CN)
YING HUA (CN)
TAO WEIKANG (CN)
Application Number:
PCT/CN2023/101778
Publication Date:
December 28, 2023
Filing Date:
June 21, 2023
Export Citation:
Assignee:
JIANGSU HENGRUI PHARMACEUTICALS CO LTD (CN)
SHANGHAI HENGRUI PHARMACEUTICAL CO LTD (CN)
SHANGHAI HENGRUI PHARMACEUTICAL CO LTD (CN)
International Classes:
C07K16/46; A61K39/395; A61P35/00; C07K16/28; C07K16/30; C07K19/00; C12N5/10; C12N15/13
Foreign References:
| CN112513092A | 2021-03-16 | |||
| CN108271376A | 2018-07-10 |
Attorney, Agent or Firm:
GE CHENG & CO., LTD. (CN)
Download PDF: